| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Rejection of renal transplantation; Purpura, Thrombotic Thrombocytopenic; Kidney Diseases; Rejection of organ transplantation; Guillain-Barre Syndrome; Renal Insufficiency, Chronic; Kidney Failure, Chronic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant Tumor Enzyme Specific Interferon α-2b Fc Fusion (Livzon Pharmaceutical Group) | A-01 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Solid tumours | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
